Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2CNS 2

Conditions

Neuroendocrine Tumors 2

Interventions

Everolimus 23pasireotide 14lutetium Lu 177 dotatate 10Octreotide 10lanreotide 9surufatinib 8Carboplatin 8Paclitaxel 7pembrolizumab 5amino-acid, glucose, and electrolyte solution 5Thyrotropin Alfa 5Sunitinib 5Nivolumab 5Injections 53-Iodobenzylguanidine 5relacorilant 4fosbretabulin 4Temozolomide 4Fulvestrant 4Etoposide 4Data Collection 4Cisplatin 4vandetanib 3selpercatinib 3dabrafenib 3anlotinib 3Mifepristone 3Lutetium-177 3Lutetium 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × 64Cu-SARTATE × Endocrine × Clear all
NCT04438304 2025-02-12

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

Clarity Pharmaceuticals Ltd

Phase 2 Completed
45 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04440956 2020-06-22

An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

Clarity Pharmaceuticals Ltd

Phase EARLY_PHASE1 Completed
10 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡